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Abstract
Background: Alpha-1-antitrypsin deficiency (AATD) is an autosomal codominant inherited disease that is significantly
underdiagnosed. We have previously shown that the combination of an awareness campaign with the offer of free
diagnostic testing results in the detection of a relevant number of severely deficient AATD patients. The present study
provides an update on the results of our targeted screening program (German AAT laboratory, University of Marburg)
covering a period from August 2003 to May 2015.
Methods: Diagnostic AATD detection test kits were offered free of charge. Dried blood samples were sent to our
laboratory and used for the semiquantitative measurement of the AAT-level (nephelometry) and the detection of the
S- or Z-allele (PCR). Isoelectric focusing was performed when either of the initial tests was indicative for at least one
mutation. Besides, we evaluated the impact of additional screening efforts and the changes of the detection rate over
time, and analysed the relevance of clinical parameters in the prediction of severe AATD.
Results: Between 2003 and 2015, 18,638 testing kits were analysed. 6919 (37.12 %) carried at least one
mutation. Of those, we identified 1835 patients with severe AATD (9.82 % of the total test population)
including 194 individuals with rare genotypes. Test initiatives offered to an unselected population resulted in
a dramatically decreased detection rate. Among clinical characteristics, a history of COPD, emphysema, and
bronchiectasis were significant predictors for Pi*ZZ, whereas a history of asthma, cough and phlegm were
predictors of not carrying the genotype Pi*ZZ.
Conclusion: A targeted screening program, combining measures to increase awareness with cost-free diagnostic
testing, resulted in a high rate of AATD detection. The clinical data suggest that testing should be primarily
offered to patients with COPD, emphysema, and/or bronchiectasis.
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Targeted screening
Background and objectives
Alpha 1-antitrypsin (AAT) deficiency (AATD), one of the
most prevalent inherited disorders in populations of
European descent, is characterized by abnormally low
serum levels of AAT [1]. The leading disease manifestations
in AATD patients are chronic obstructive pulmonary
disease (COPD) with early onset emphysema, particularly
in individuals who smoke. Further associated diseases com-
prise liver disease, cutaneous panniculitis, bronchiectasis,
vasculitis, Wegener’s granulomatosis and lung cancer [2–6].
To date, more than 100 genetic variants of the AAT
gene (SERPINA1) have been identified [7]. The protein-
ase inhibitor (PI) MM genotype is the predominant
phenotype amongst those considered as normal whereas
most individuals with severe AATD are homozygous
PI*ZZ (or Pi*Z0, Pi*00) showing a significantly reduced
AAT serum concentration [8, 9]. Reports based on gen-
etic epidemiologic surveys estimate that about 180.000
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individuals worldwide carry the phenotype Pi*ZZ [10].
In contrast, recent data from the European Alpha-1
international registry (AIR) indicate 4.758 registered
individuals with severe deficiency implying that only
3,8 % of the severely affected individuals have been iden-
tified [11]. Besides, several studies have demonstrated
substantial delays in the diagnosis of AATD [12, 13]. On
average, AATD patients experience a diagnostic delay of
6 years and have to consult three physicians until the
diagnosis is established [14]. The average age of diagno-
sis for AATD patients is 45.5 years, but one third is not
diagnosed until their fifties [12].
ATS (American Thoracic Society)/ERS (European Re-
spiratory Society) and WHO provided recommendations
for genetic testing in order to enhance the detection of
severe AATD patients [1, 15]. Briefly, according to the
WHO all individuals with COPD, emphysema or asthma
or with a family history of the disorder should be
screened once for AATD using a quantitative test [15].
ATS and ERS guidelines recommend testing for all
patients with COPD, emphysema, or asthma with irre-
versible airflow obstruction [1]. Interventions under-
taken to identify AATD individuals include screening
and targeted detection studies [16]. Screening studies
investigate unselected groups without suspicion of hav-
ing AATD whereas targeted (case-finding) studies focus
on individuals with a high risk for AATD. As a result,
targeted approaches achieve much higher rates of detec-
tion of AATD: Several studies reported detection rate of
Pi*ZZ ranging from 0.37 to 12 % [17], depending on the
location, the inclusion criteria and the number of indi-
viduals investigated.
In the present paper, we provide an update on the
results of our targeted screening program (German AAT
laboratory, University of Marburg) covering the period
of August 2003 to September 2015 and including the
results of 18,683 test kits.
Methods
The present study gives an update of the German targeted
screening program which has been already described in
detail [18]. Briefly, it combines a diagnostic service (offer-
ing a cost-free diagnostic test concerning AATD) with the
aim to increase the awareness of physicians with regard to
potential AATD individuals. The diagnostic approach
combines the initial measurement of the AAT serum level
and a targeted PCR to detect the two most common mu-
tations (Pi*S and Pi*Z) with further testing (genotyping,
gene sequencing) if necessary [18].
Furthermore, “screening events” have been carried out:
In these events (most often performed after a meeting of
patient organizations), all individuals were invited to
undergo testing, regardless of presence/absence of re-
spiratory symptoms or a serum level. All patients gave
informed consent for genetic testing. Because the study
reflects a retrospective analysis of routine data, an ethics
approval was not necessary.
Diagnostic approach
All samples underwent nephelometry for determination
of the AAT-level and PCR for the detection of the S-
and Z-allele, which was eventually followed by isoelectic
focusing and gene sequencing. The results of PCR and
IEF were read out and combined by two independent
readers. Details regarding the laboratory methods used
can be found in the online supplement (Additional file 1:
Details on laboratory methods) and have been described
before [18].
The results were reported to the medical doctor who
had sent the testing kit. All procedures were quality con-
trolled and based on standard operating procedures
(SOPs). All laboratory procedures included appropriate
negative and positive controls. The AATD Laboratory
Marburg participates successfully in interlaboratory
comparisons.
Data storage and analysis
The test results were entered into a Microsoft Access
database. To compare detection rates between the over-
all results and screening events only, Fisher’s exact test
was used. To analyse the effect of the presence/absence
of symptoms on the pre-test probability to identify
Pi*ZZ, a multiple logistic regression analysis was per-
formed with the following parameters: Pi*ZZ as being
the dependent variable and clinical characteristics that
were recorded on the kit (acute bronchitis, asthma,
bronchiectasis, COPD, dyspnoea on exertion, dyspnoea
attacks, emphysema, chronic bronchitis, cough, sputum,
wheezing) being the independent variables. All analyses
were carried out using SPSS Version 20 (IBM, Ehningen,
Germany), and GraphPad Prism Version 6 (GraphPad
Software, Inc., La Jolla, USA).
Results
From August 2003 to September 2015, >50,000 test kits
were sent out on request. A total number of 19,121 kits
were received in our laboratory for analysis (500 – 2500
per year); 57 were not analyzable (not enough material:
n = 18; missing data: n = 39) and 381 had been submitted
more than once. Therefore, our final analysis includes
18,683 samples (Fig. 1).
We identified 6919 patients with at least one defi-
ciency allele (37.12 %) including 271 individuals with
rare genotypes. In descending order of frequency, we
have diagnosed the following genotypes (Fig. 2): Pi*MM
(11764; 62.97 %), Pi*MZ (4011; 21.47 %), Pi*ZZ (1293;
6.92 %), Pi*MS (941; 5.04 %), Pi*SZ (348; 1.86 %), Pi*SS
(55; 0.29 %). In samples that underwent gene sequencing
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(results not clear after standard PCR and IEF), we found
271 rare genotypes.
Compared to the overall results of the laboratory, the
screening events yielded significantly less positive results
(at least one deficiency allele) (Table 1).
After an initial drop of the detection rate (% samples
Pi*ZZ in a given time period), the rate increased from
2008/09 over the following years. Exploring potential
reasons for that we described the three most frequent
clinical characteristics that led to screening (Table 2).
We found that time periods associated with high detec-
tion rates included either emphysema or COPD while
the time periods with the lowest detection rates (2008/
09 and 2010/11) did not (Table 2).
In a multivariate logistic regression analysis of clinical
features of the individuals that underwent testing, we found
emphysema, bronchiectasis and COPD being the strongest
predictors of Pi*ZZ (Fig. 3). Acute bronchitis, chronic
bronchitis, cough, wheezing, and phlegm were associated
with decreased likelihood of detecting Pi*ZZ (Fig. 3).
Discussion
From 2003 to 2015, we analyzed 18,683 DBS samples with
PCR and nephelometry in our AAT diagnostic laboratory
in Marburg, Germany. In 1835 (9.82 %) of these we identi-
fied an individual with severe AATD. Our results corres-
pond to those of other laboratories that have initiated
Fig. 1 Over 50,000 test kits have been distributed. Kits from patients
that had already been tested (n= 381) and kits that were not analyzable
(n= 57) were removed from the final analysis
Fig. 2 Results from 18,683 kits that have been analysed successfully within the first 12 years of the laboratory (August 2003 to September 2015)
Table 1 Results of screening events (n = 1048) compared to the
results of the entire test population (n = 17,635). Displayed are
percentage numbers of the laboratory population (left column)
and the screening event population, respectively (right column)
Laboratory Screening p-value
Population Event (Fisher-Test)
MM 63.48 88.02 <0.001
MS 5.05 4.56 0.62
MZ 20.38 5.13 <0.001
SZ 1.88 0.16 <0.001
SS 0.31 0.08 0.25
ZZ 7.09 0.07 <0.001
Rare 1.44 0 <0.01
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targeted detection regarding AATD and focus on test
populations showing clinical features of the disease.
The Italian program distributing DBS AATD tests to
hospitals and clinics suggested testing of individuals
with early-onset emphysema and familial cluster of
COPD, with a plasma AAT level <80 mg/dl or first de-
gree relatives of subjects with known AATD (including
Pi*MZ heterozygosity) [19, 20]. Of 2127 samples,
10.6 % presented with severe deficiency (Pi*ZZ, Pi*SZ
and rare genotypes). Carroll et al. screened 3000 individ-
uals as part of the Irish National Targeted Detection
Programme and included subjects with COPD, non-
responsive asthma, cryptogenic liver disease, first degree
relatives of AATD patients and individuals with reduced
serum AAT levels [21]. 3.1 % were found to have a severe
deficiency. Corda et al. chose an extremely selected study
population displaying specific characteristics of AATD in
order to perform a targeted screening study and identified
15.8 % severely deficient phenotypes (12 % Pi*ZZ) in a
rather small study sample (n = 285) [22]. On the other
hand, screening studies including non-selected patients
with COPD or other respiratory clinical syndromes were
not able to detect severe AATD phenotypes in more than
0.5 % of the study population [23–25]. These data once
more underline the importance of careful selection re-
garding individuals suspected to have AATD when
performing a targeted screening program. To our know-
ledge, our analysis represents the as yet biggest targeted
screening cohort in Europe (n = 18,683). According to
estimates of the frequency of Pi*ZZ in Germany [26],
8003 individuals would be expected. Having detected 1293
individuals (16.15 %) is a higher percentage than has been
reported in many other countries of the world as pointed
out by a recent review [27].
Comparing our data to those previously published [18]
we were able to document stability of the results over time
which might derive from the continuous preselection of
the study population, the high number of analyzed sam-
ples and the experience of the Marburg laboratory with
applying diagnostic methods concerning AATD. While
the results remained rather stable comparing the first
published analysis with the recent one, it has to be ac-
knowledged that there was a drop in the detection rate dur-
ing 2008 – 2011 (Table 2). The increase after that may – at
least in part – be explained by COPD becoming a more
prominent cause to send samples to our laboratory, reflect-
ing a population being more likely to suffer from severe
AATD (Table 2). Regarding the relatively high detection
rate in 2003 – 2005, younger patients with emphysema
have been tested, again a population more likely to carry a
severe deficiency SERPINA1 genotype (Table 2).
By using our test algorithm, we intended to investigate
especially those patients who showed low concentrations
of AAT levels in order to prevent unnecessary diagnostic
steps and save costs. On the other hand, heterozygous
carriers of SERPINA1 mutations may have been missed
because the determination of the AAT level precedes
sending of tests to our laboratory. Ferrarotti et al.
(University of Pavia) perform genotyping (by PCR-
Table 2 Displayed are the detection rates (Pi*ZZ) of different
time periods, the characteristics of the population screened at
that time (age in years; mean ± standard deviation) and the
three most frequent clinical characteristics that led to the test
initiation. Numbers do not add up to 18,683, because for some
individuals the gender was not recorded and could not be
deducted by the name
Detection
rate [%]
Age [years] Male/female Most frequent clinical
characteristics
2003/04/05 8.65 39.8 ± 21.9 1105/887 1. Cough
2. Emphysema
3. Wheezing
2006/07 4.04 40.4 ± 21.7 1527/1399 1. Dyspnoea on exertion
2. Cough
3. Wheezing
2008/09 4.25 48.9 ± 21.6 1973/1791 1. Dyspnoea on exertion
2. Cough
3. Phlegm
2010/11 4.98 48.2 ± 20.3 2127/1888 1. Dyspnoea on exertion
2. Cough
3. Phlegm
2012/13 7.91 47.9 ± 19.1 1808/1661 1. Dyspnoea on exertion
2. Cough
3. COPD
2014/15 11.26 48.5 ± 18.8 1280/1139 1. Dyspnoea on exertion
2. COPD
3. Cough
All 6.85 45.9 ± 20.8 9820/8765 1. Dyspnoea on exertion
2. Cough
3. COPD
Fig. 3 Clinical characteristics predictive for the genotype Pi*ZZ
(multivariate logistic regression analysis)
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RFLP using TaqI as the restriction enzyme) at the first
stage of their algorithm simultaneously with the quantita-
tive measurement of AAT-levels [28], resulting in a higher
rate of testing in samples with normal AAT-levels. Fur-
thermore, the testing algorithm used by the laboratory of
the university in Pavia allows consecutive sequence ana-
lyses if the results of the phenotyping do not produce clear
evidence about deficiency phenotypes whereas our labora-
tory repeats nephelometry, PCR and IEF in whole blood
samples of individuals with conflicting results from DBS
analyses before performing additional DNA sequencing.
We detected a relatively high number of rare geno-
types other than Pi*ZZ or Pi*SZ among the individuals
with severe AATD (194/1835 = 10.57 %) which is more
than, for example, the rate of 1.7 % reported by the
NHLBI Registry [29], and comparable with results pub-
lished by Ferrarotti et al. who recorded an 11 % prevalence
of subjects with severe AATD carrying rare variants [30].
In the light of a new test that identifies individuals with a
Z-allele but would not detect individuals with severe defi-
ciency without one or two Z alleles [31] it is reassuring to
notice that only very few individuals (22 S/rare, 17 rare/
rare) would be missed by this test.
The majority of kits was returned by pulmonologists
reflecting the pulmonary symptoms most patients with
symptomatic AATD suffer. The low number of gastro-
enterologists who returned DBS to our laboratory
might be explained by the fact that liver problems
deriving from an underlying AATD occur directly after
birth. During this phase of life testing will be usually re-
quested by the pediatricians. Evaluating targeted AATD
screening programs should also include the aspect of
cost-effectiveness. In fact, it has been shown that case-
finding in populations in which AATD is suspected in
reasonable frequency (e.g. patients with known COPD)
could satisfy cost-effectiveness criteria [32]. In line with
this, our testing algorithm reveals its potential to save
costs by applying phenotyping (<50 % IEF) and sequen-
cing (~1 %) in a limited number of individuals.
With regard to clinical characteristics that would be pre-
dictive for Pi*ZZ we confirmed earlier reports of COPD
and emphysema being important predictors. The fact that
bronchiectasis was a strong predictor for Pi*ZZ is inter-
esting, because earlier reports gave conflicting results
[33–35]. Our results would support screening for
AATD in this patient group that is increasingly
recognized [36]. Asthma and acute bronchitis were the
strongest clinical predictors of not carrying a homozygous
deficiency. This confirms studies that did not report an
increased prevalence of homozygous AATD in asthmatic
patients [37, 38].
Concerning potential limitations of our screening pro-
gram we acknowledge that targeting selected (symptom-
atic) individuals might result in missing asymptomatic
subjects with severe AATD. This has been suggested by
several studies which investigated the percentage of Pi*ZZ
individuals with clinical symptoms. A significant proportion
of homozygote Pi*ZZ subjects do neither develop emphy-
sema [39] nor COPD [40]. Besides, we have only limited
information about the patients, their clinical characteristics
or serum AAT levels. Reporting symptoms (beyond the
clinical characteristics that have been asked for), lung
function, smoking habits and family screening would have
been helpful in characterizing AATD individuals.
Conclusions
In conclusion, we have shown that our targeted screen-
ing program, combining an awareness campaign with
cost-free diagnostic testing, resulted in a high rate of
AATD detection, especially in patients with COPD, em-
physema, and bronchiectasis. In the context that AATD
is still an under-diagnosed disease and that recognition
may entail important implications (e.g. smoking avoid-
ance, family testing, augmentation therapy), targeted
screening approaches should be continued.
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